TR199903214T2 - Bir antitümör maddesi ve bir hidroksimik asit türevini ihtiva eden, antitümör etkinligi arttirilmis ve yan etkileri düsürülmüs farmasötik bilesim. - Google Patents

Bir antitümör maddesi ve bir hidroksimik asit türevini ihtiva eden, antitümör etkinligi arttirilmis ve yan etkileri düsürülmüs farmasötik bilesim.

Info

Publication number
TR199903214T2
TR199903214T2 TR1999/03214T TR9903214T TR199903214T2 TR 199903214 T2 TR199903214 T2 TR 199903214T2 TR 1999/03214 T TR1999/03214 T TR 1999/03214T TR 9903214 T TR9903214 T TR 9903214T TR 199903214 T2 TR199903214 T2 TR 199903214T2
Authority
TR
Turkey
Prior art keywords
antithyroid
side effects
reduced side
increased
pharmaceutical composition
Prior art date
Application number
TR1999/03214T
Other languages
English (en)
Inventor
Sumegi Balazs
Original Assignee
N-Gene Research Laboratories Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by N-Gene Research Laboratories Inc. filed Critical N-Gene Research Laboratories Inc.
Publication of TR199903214T2 publication Critical patent/TR199903214T2/tr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Bulus, antitümör etkisine sahip olan bir bilinen aktif maddeyi ya da bu maddenin farmasötik açidan kabul edilebilir bir tuzunu ve (I) formülünün bir hidrosimik asit türevini ya da bu türevin bir terapötik açidan yararli asit ilave tuzunu içeren, antitümör etkinligi arttirilmis ya da yan etkileri düsürülmüs farmasötik bilesimlerine iliskindir.
TR1999/03214T 1997-06-23 1998-06-22 Bir antitümör maddesi ve bir hidroksimik asit türevini ihtiva eden, antitümör etkinligi arttirilmis ve yan etkileri düsürülmüs farmasötik bilesim. TR199903214T2 (tr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
HU9701081A HU9701081D0 (en) 1997-06-23 1997-06-23 Pharmaceutical composition of antitumoral activity

Publications (1)

Publication Number Publication Date
TR199903214T2 true TR199903214T2 (tr) 2000-12-21

Family

ID=89995266

Family Applications (1)

Application Number Title Priority Date Filing Date
TR1999/03214T TR199903214T2 (tr) 1997-06-23 1998-06-22 Bir antitümör maddesi ve bir hidroksimik asit türevini ihtiva eden, antitümör etkinligi arttirilmis ve yan etkileri düsürülmüs farmasötik bilesim.

Country Status (24)

Country Link
US (4) US6440998B1 (tr)
EP (1) EP0993304B1 (tr)
JP (1) JP2002508762A (tr)
KR (1) KR20010020496A (tr)
CN (1) CN1127984C (tr)
AT (1) ATE235918T1 (tr)
AU (1) AU735922B2 (tr)
BR (1) BR9810312A (tr)
CA (1) CA2294913C (tr)
CZ (1) CZ298468B6 (tr)
DE (1) DE69812949T2 (tr)
DK (1) DK0993304T3 (tr)
ES (1) ES2195344T3 (tr)
HU (1) HU9701081D0 (tr)
IL (1) IL133508A (tr)
NO (1) NO322206B1 (tr)
NZ (1) NZ502039A (tr)
PL (1) PL191718B1 (tr)
PT (1) PT993304E (tr)
RU (2) RU2254129C2 (tr)
SK (1) SK282877B6 (tr)
TR (1) TR199903214T2 (tr)
UA (1) UA64757C2 (tr)
WO (1) WO1998058676A1 (tr)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6884424B2 (en) * 1995-12-22 2005-04-26 N-Gene Research Laboratories Inc. Method for treating the pathological lesions of the skin that develop by ultraviolet radiation of the sunlight
US20030158220A1 (en) * 1997-11-03 2003-08-21 Foss Joseph F. Use of methylnaltrexone and related compounds to treat chronic opioid use side effects
ES2528669T3 (es) * 2003-04-08 2015-02-11 Progenics Pharmaceuticals, Inc. Formulaciones farmacéuticas que contienen metilnaltrexona
FR2878749B1 (fr) * 2004-12-03 2007-12-21 Aventis Pharma Sa Combinaisons antitumorales contenant en agent inhibiteur de vegt et du 5fu ou un de ses derives
US8524731B2 (en) 2005-03-07 2013-09-03 The University Of Chicago Use of opioid antagonists to attenuate endothelial cell proliferation and migration
US9662325B2 (en) 2005-03-07 2017-05-30 The University Of Chicago Use of opioid antagonists to attenuate endothelial cell proliferation and migration
US8518962B2 (en) 2005-03-07 2013-08-27 The University Of Chicago Use of opioid antagonists
WO2006096626A2 (en) * 2005-03-07 2006-09-14 The University Of Chicago Use of opioid antagonists to attenuate endothelial cell proliferation and migration
AR057325A1 (es) * 2005-05-25 2007-11-28 Progenics Pharm Inc Sintesis de (s)-n-metilnaltrexona, composiciones farmaceuticas y usos
AR057035A1 (es) * 2005-05-25 2007-11-14 Progenics Pharm Inc SíNTESIS DE (R)-N-METILNALTREXONA, COMPOSICIONES FARMACÉUTICAS Y USOS
TWI489984B (zh) 2006-08-04 2015-07-01 Wyeth Corp 用於非經腸道傳輸化合物之配方及其用途
TW200817048A (en) * 2006-09-08 2008-04-16 Wyeth Corp Dry powder compound formulations and uses thereof
US7763601B2 (en) * 2006-11-02 2010-07-27 N-Gene Research Laboratories, Inc. Prevention and treatment of obesity
US20080108602A1 (en) * 2006-11-02 2008-05-08 N-Gene Research Laboratories, Inc. Prevention of obesity in antipsychotic, antidepressant and antiepileptic medication
PE20090700A1 (es) * 2007-03-29 2009-07-13 Progenics Pharm Inc Compuestos heterociclicos como antagonistas del receptor opioide periferico
PL2139890T3 (pl) * 2007-03-29 2014-11-28 Wyeth Llc Antagoniści obwodowych receptorów opioidowych i ich zastosowania
BRPI0809579B8 (pt) 2007-03-29 2021-05-25 Progenics Pharm Inc formas cristalinas e seus usos
NZ584849A (en) * 2007-10-30 2012-04-27 Trophos Novel composition for treating the side effects of anticancer treatments
WO2009074835A1 (en) * 2007-12-10 2009-06-18 N-Gene Research Laboratories Inc. Dose reduction of a cannabinoid cb1 receptor antagonist in the treatment of overweight or obesity
WO2009099411A1 (en) 2008-02-06 2009-08-13 Progenics Pharmaceuticals, Inc. Preparation and use of (r),(r)-2,2'-bis-methylnaltrexone
AU2009225434B2 (en) 2008-03-21 2014-05-22 The University Of Chicago Treatment with opioid antagonists and mTOR inhibitors
CA2676881C (en) 2008-09-30 2017-04-25 Wyeth Peripheral opioid receptor antagonists and uses thereof
ITMI20110791A1 (it) 2011-05-09 2012-11-10 Probiotical Spa Ceppi di batteri in grado di metabolizzare gli ossalati.
ITMI20110793A1 (it) 2011-05-09 2012-11-10 Probiotical Spa Ceppi di batteri probiotici e composizione sinbiotica contenente gli stessi destinata alla alimentazione dei neonati.
ITMI20110792A1 (it) 2011-05-09 2012-11-10 Probiotical Spa Ceppi di batteri appartenenti al genere bifidobacterium per uso nel trattamento della ipercolesterolemia.
HUP1100445A2 (en) 2011-08-17 2013-02-28 Pharma Gene Sa Pharmaceutical composition
HUP1100444A2 (en) 2011-08-17 2013-02-28 Pharma Gene Sa Pharmaceutical composition
RU2522548C2 (ru) * 2012-09-26 2014-07-20 Федеральное государственное бюджетное учреждение науки Институт кристаллографии им. А.В. Шубникова Российской академии наук (ИК РАН) Ингибитор уридинфосфорилаз
US9938279B2 (en) * 2013-04-09 2018-04-10 Energenesis Biomedical Co., Ltd Method for treating disease or condition susceptible to amelioration by AMPK activators and compounds of formula which are useful to activate AMP-activated protein kinase (AMPK)
CN116492347A (zh) * 2013-09-18 2023-07-28 华安医学股份有限公司 一种活化ampk的化合物及其用途
ITUA20162013A1 (it) 2016-03-24 2017-09-24 Probiotical Spa Composizione a base di batteri lattici per il trattamento contemporaneo di infezioni vaginali di origine micotica e batterica.
RU2679136C1 (ru) * 2018-03-13 2019-02-06 Федеральное государственное бюджетное научное учреждение "Федеральный исследовательский центр "Красноярский научный центр Сибирского отделения Российской академии наук" (ФИЦ КНЦ СО РАН, КНЦ СО РАН) Способ получения препарата на основе взаимодействия цис-диамин(циклобутан-1,1-дикарбоксилат-о,о')платины(ii) с арабиногалактаном
HUP1800298A1 (hu) 2018-08-30 2020-05-28 N Gene Res Laboratories Inc Gyógyszerkombináció béta-receptor blokkolók hatásának módosítására és a mellékhatások csökkentésére

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4308399A (en) * 1977-08-30 1981-12-29 Chinoin Gyogyszer Es Vegyeszeti Termekek Gyara Rt. O-(3-Amino-2-hydroxy-propyl)-amidoxime derivatives, process for the preparation thereof and pharmaceutical compositions containing same
US4599361A (en) * 1985-09-10 1986-07-08 G. D. Searle & Co. Hydroxamic acid based collagenase inhibitors
HU207988B (en) * 1988-10-20 1993-07-28 Biorex Kutato Fejlesztoe Kft Process for producing halogenides of o-/3-amino-2-hydroxy-propyl/hydroximic acid and pharmaceutical compositions containing them as active components
HUT54347A (en) * 1989-01-10 1991-02-28 Chinoin Gyogyszer Es Vegyeszet Improved process for producing amidoximes
JPH05125029A (ja) * 1991-11-06 1993-05-21 Yamanouchi Pharmaceut Co Ltd 新規なアミド化合物又はその塩
PL310895A1 (en) * 1993-03-31 1996-01-08 Merck & Co Inc Hiv protease inhibitors in aids treating pharmaceutic compositions
TW381025B (en) * 1993-08-05 2000-02-01 Hoffmann La Roche Pharmaceutical composition containing a glucosidase inhibitor and a lipase inhibitor
HU9502843D0 (en) * 1995-09-29 1995-11-28 Livigene Ltd Pharmaceutical composition
UA64716C2 (en) * 1996-08-09 2004-03-15 Pharmaceuticals for therapy or prevention of illnesses connected with dysfunction of vascular endothelial cells

Also Published As

Publication number Publication date
US6720337B2 (en) 2004-04-13
HK1029941A1 (en) 2001-04-20
DK0993304T3 (da) 2003-07-28
PL191718B1 (pl) 2006-06-30
US20020147213A1 (en) 2002-10-10
EP0993304A1 (en) 2000-04-19
RU2254129C2 (ru) 2005-06-20
IL133508A0 (en) 2001-04-30
CA2294913C (en) 2008-12-16
PL337719A1 (en) 2000-08-28
EP0993304B1 (en) 2003-04-02
US6656955B2 (en) 2003-12-02
UA64757C2 (uk) 2004-03-15
SK282877B6 (sk) 2003-01-09
KR20010020496A (ko) 2001-03-15
IL133508A (en) 2005-11-20
ATE235918T1 (de) 2003-04-15
US6440998B1 (en) 2002-08-27
JP2002508762A (ja) 2002-03-19
US20030069270A1 (en) 2003-04-10
AU735922B2 (en) 2001-07-19
BR9810312A (pt) 2000-09-19
NO996349D0 (no) 1999-12-20
SK176499A3 (en) 2000-09-12
CN1127984C (zh) 2003-11-19
ES2195344T3 (es) 2003-12-01
CZ462599A3 (cs) 2000-05-17
PT993304E (pt) 2003-08-29
CN1263471A (zh) 2000-08-16
RU2214238C2 (ru) 2003-10-20
US6838469B2 (en) 2005-01-04
WO1998058676A1 (en) 1998-12-30
CA2294913A1 (en) 1998-12-30
US20030050345A1 (en) 2003-03-13
DE69812949D1 (de) 2003-05-08
NO996349L (no) 2000-02-23
NO322206B1 (no) 2006-08-28
AU7783798A (en) 1999-01-04
NZ502039A (en) 2002-03-28
CZ298468B6 (cs) 2007-10-10
DE69812949T2 (de) 2004-02-05
HU9701081D0 (en) 1997-08-28

Similar Documents

Publication Publication Date Title
TR199903214T2 (tr) Bir antitümör maddesi ve bir hidroksimik asit türevini ihtiva eden, antitümör etkinligi arttirilmis ve yan etkileri düsürülmüs farmasötik bilesim.
NO962841D0 (no) Anvendelse av 2-hydroksy-5-fenylazobenzosyrederivater som colon cancer kjemopreventativer og kjemoterapeutiske midler
TR199900674T2 (tr) Kinazolin türevleri ve bunlari içeren farmasötik bilesimler.
AP1760A (en) Platinum derivative pharmaceutical formulations.
TR199902383T2 (tr) Yeni pirimidin türevleri ve bunlarin hazirlanmasi için proses.
TR200001645T2 (tr) Retinoyik asit taklidi anilürler.
TR199802344A2 (tr) Ikame edilmis imidazolidin türevleri
PT902789E (pt) Derivados de androsteno
TR199900336T2 (tr) EAA antagonistleri olarak tetrahidrokinolin türevleri.
WO2000045800A3 (en) Immunosurpressive effects of pteridine derivatives
ATE316782T1 (de) Neue orale formulierungen für 5-ht4 agonisten oder antagonisten
TR199802384T2 (tr) Nörodejeneratif hastaliklarin tedavisinde yararli farmasötik bilesimlerin hazirlanmasi için P-Aminofenol türevlerinin kullanimi.
RU95113437A (ru) (h±)-сложный этиловый эфир транс-2-диметиламино-1-фенил-3-циклогексентранс-1-карбоновой кислоты в виде первичного ортофосфата и твердая фармацевтическая композиция с обезболивающей активностью
DK0773782T3 (da) Terpenderivater (sarcodictyiner) anvendelse som antitumormidler
TR199903272T2 (tr) Astim karsiti ilaçlarin yeni bilesimleri.
TR199901380A2 (tr) Di-ya da triazo-spiro[4,5] dekan türevleri
PT1107750E (pt) Composicao farmaceutica, a base de carboplatina, com actividade anti-tumor
PT930877E (pt) D-metionina para reduzir a toxicidade de compostos antitumorais contendo platina
DE60003328D1 (de) Ruthenium (ii) komplexe mit hoher antitumor und antimetastatischer wirkung